Piper Jaffray Downgrades Neothetics Inc. (NEOT) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Needham & Company Downgrades Neothetics Inc. (NEOT) to Hold
December 15, 2015 7:20 AM ESTNeedham & Company downgraded Neothetics Inc. (NASDAQ: NEOT) from Buy to Hold after the company announced that its pivotal clinical program (consisting of studies AbCONTOUR-1 and -2) evaluating LIPO-202 for the reduction of central abdominal bulging did not meet the primary or any of the secondary... More
Neothetics (NEOT) Reports LIPO-202 Phase 3s Missed co-Primary, Secondary Endpoints
December 14, 2015 4:31 PM ESTNeothetics, Inc. (NASDAQ: NEOT) announced top-line results from its AbCONTOUR1 and AbCONTOUR2 U.S.-based pivotal Phase 3 trials to evaluate the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat. In both studies, LIPO-202 did not meet its co-primary composite and secondary endpoints. The co-primary endpoints were the proportion of subjects who reported an improvement of at least one point on the Patient-Global Abdominal Perception Scale (P-GAPS) and an improvement of at least two points on... More
